RxDoctor Payments Data

Ryan Boland, MD

Ophthalmology · Savannah, GANPI 1558343798

Payments from drug & device makers

$3,481in general payments, 2019–2025

Across 172 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$955
  • Alcon$411
  • AbbVie$405
  • Bausch & Lomb Americas Inc.$320
  • Kala Pharmaceuticals, Inc.$172
  • Novartis$166
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$201%
  • Food & beverage$3,46099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,481 in reported general payments places this provider in the 60th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$203,787
Medicare patients
811
Services billed
2,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost159$62,038
RestasisCyclosporine70$59,319
XiidraLifitegrast58$51,855
VyzultaLatanoprostene Bunod139$47,637
XdemvyLotilaner23$42,142
LumiganBimatoprost74$35,962
Cyclosporine53$26,243
SimbrinzaBrinzolamide/Brimonidine Tart117$24,397
TyrvayaVarenicline Tartrate19$12,499
MieboPerfluorohexyloctane/Pf14$10,453
RhopressaNetarsudil Mesylate28$10,266
Brimonidine Tartrate106$4,861
Latanoprost364$4,202
Travoprost16$3,865
Dorzolamide Hcl153$2,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$320$109,945211 claims
AbbVieRestasis, Lumigan, Combigan$405$97,695155 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$141$72,304187 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$75$42,14223 claims
AlconSimbrinza$411$24,397117 claims
Oyster Point Pharma, Inc.Tyrvaya$140$12,49919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →